Bacteriophages: Antibacterials with a future?

Medical Hypotheses

Volumn 62, Issue 6, 2004, Pages 889-893

  Broxmeyer, Lawrence ^a  

^a Med America Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ISONIAZID; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BODY FLUID; CELL VACUOLE; DRUG EFFICACY; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HUMAN; HYPOTHESIS; INJECTION; INTRACELLULAR SPACE; LEUKOCYTE; LYSOGENIZATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VIRUS VIRULENCE;

BACILLI; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; UNIDENTIFIED BACTERIOPHAGE;

EID: 2542459473     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.002     Document Type: Article

References (29)

1. Lewis S. Arrowsmith. New York: New American Library; 1961.
2. Eaton MD, Bayne-Jones S. Bacteriophage therapy. Council on pharmacy and chemistry. JAMA 1934.
3. Surveillance TWIGP Anti-tuberculosis drug resistance in the world. Geneva: World Health Organization Global Tuberculosis Programme, 1977.
4. Falkinham JO. Third epidemiology of infection by nontuberculosis mycobacteria. Clin Microbiol Rev 1996;9:177-215.
5. Bloom B. Tuberculosis: pathogenesis, protection and control. Washington, DC: American Society for Microbiology Press; 1995.
6. Levin BR, Bull JJ. Phage therapy revisited. The population biology of a bacterial infection and its treatment with.... Am Nat 1996;147(6):881.
7. Sula L. Therapy of experimental tuberculosis in Guinea Pigs with mycobacterial phages DS-6A, GR21T, MY-327. Czech Med 1981;4(4):209-14.
8. Iseman MD. Evolution of drug resistant tuberculosis: a tale of two species. Proc Natl Acad Sci USA 1994;91:2428-9.
9. Naik G. Agency to unveil anoint assault on TBTB see Mycobacterium tuberculosis and HIVHIV. Wall Street J 2002.
10. Kaplan JE, Hanson D. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-S14.
11. Waksman SA. The conquest of tuberculosis. University of California Press; 1964.
12. Salazar L. Organization of the origins of replication of the chromosomes of Mycobacteria smegmatis., Mycobacterium leprae and Mycobacterium tuberculosis and isolation of a functional origin from M. smegmatis. Mol Microbiol 1996;20(2):283-93.
13. Sula L, Sulova J, Stolcpartova M. Therapy of experimental tuberculosis in guinea. Czech Med 1981;4:209-14.
14. Brenner S, Cesaveni G. Phasmids: hybrids between CO1E1 plasmids and E. coli bacteriophage lambda. Gene 1982;17:27-44.
15. Broxmeyer L, Sosnowska D, Miltner E, Chacon O, Wagner D, McGarvey J, Barletta RG, Bermudez LE. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 2002;186(8).
16. Youman's GP. Tuberculosis. Philadelphia: W.B. Saunders Company; 1979.
17. Rich AR. The pathogenesis of tuberculosis. 2nd ed. Springfield Illinois: Charles C. Thomas Publisher; 1946.
18. Ford ME, Stenstrom C. Mycobacteriophage TM4: genome structure and gene expression. Tuber Lung Dis 1998;79(2):63-73.
19. Eremeev VV, Maiorov KB. An experimental analysis of Mycobacterium smegmatis as a possible vector for the design of a new tuberculosis vaccine. Probl Tuberk 1996;1:49-51.
20. Pethe K, Puech V. Mycobacterium smegmatis lamin-binding glycoprotein shares epitopes with Mycobacteria tuberculosis heparin-binding haemagglutin. Mol Microbiol 2001;39(1):89.
21. David HL, Jones WD. Biosynthesis of a lipase by Mycobacterium smegmatis ATTC 607 infected by mycobacteriophage D29. Am Rev Respir Dis 1970;102(5):818-20.
22. Ford ME, Stenstrom C. Mycobacteriophage TM4: genome structure and gene expression. Tuber Lung Dis 1998;79(2):63-73.
23. Wallace Jr RJ. Human disease due to Mycobacterium smegmatis. J Infect Dis 1988;58(1):52-9.
24. Newton Jr JA, Weiss PJ. Soft-tissue infection due to Mycobacterium smegmatis: report of two cases. Clin Infect Dis 1993;16(4):531-3.
25. Schreiber J, Burkhardt U. Non-tubercular mycobacterial infection of the lungs due to Mycobacterium smegmatis. Pneumologue 2001;55(5):238-43.
26. Bange FC, Collins FM. Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tuber Lung Dis 1999; 79(3):171-80.
27. Mankiewicz E. Bacteriophages that lyse mycobacteria and corynebacteria and show cytopathogenic effect on tissue cultures of renal cells of cercopithecus aethiops. Can Med Assn J 1965;92:31-3.
28. Redmond WB. Mycobacterial variations as influenced by phage and other genomic factors. Pneumonologie/Pneumonology 1970;142:191-7.
29. Dubos RJ, Straus JH. Multiplication of bacteriophages in vivo and its protective effect against an experimental infection with Shigella Dysenteriae. J Exp Med 1943;78(3): 161-8.